TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF EUROPE MEDICINAL MUSHROOM MARKET 11
1.4 LIMITATIONS 12
1.5 MARKETS COVERED 12
2 MARKET SEGMENTATION 14
2.1 MARKETS COVERED 14
2.2 GEOGRAPHICAL SCOPE 15
2.3 YEARS CONSIDERED FOR THE STUDY 15
2.4 CURRENCY AND PRICING 15
2.5 DBMR TRIPOD DATA VALIDATION MODEL 16
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 19
2.7 MULTIVARIATE MODELLING 20
2.8 TYPE LIFELINE CURVE 20
2.9 DBMR MARKET POSITION GRID 21
2.10 MARKET APPLICATIONS COVERAGE GRID 22
2.11 SECONDARY SOURCES 23
2.12 ASSUMPTIONS 23
3 EXECUTIVE SUMMARY 24
4 PREMIUM INSIGHTS 26
5 MARKETING STRATEGIES 27
6 MARKET OVERVIEW 28
6.1 DRIVERS 30
6.1.1 HIGH NUTRITIONAL, AND MEDICINAL VALUE OF MEDICINAL MUSHROOMS 30
6.1.2 DIVERSE APPLICATION OF MEDICINAL MUSHROOMS IN COSMETICS 30
6.1.3 GROWING AWARENESS ABOUT THE HEALTH BENEFITS OF MEDICINAL MUSHROOMS 30
6.2 RESTRAINTS 31
6.2.1 FLUCTUATING PRICES OF MEDICINAL MUSHROOMS 31
6.2.2 AVAILABILITY OF SUBSTITUTES FOR MEDICINAL MUSHROOMS 31
6.3 OPPORTUNITIES 31
6.3.1 INCREASING CASES OF VARIOUS DISEASES 31
6.3.2 INCREASING APPLICATIONS OF MEDICINAL MUSHROOMS IN THE FOOD 32
6.3.3 INCREASING VEGAN POPULATION DEMANDING A PROTEIN-RICH DIET 33
6.4 CHALLENGES 33
6.4.1 HIGH PRICES OF MEDICINAL MUSHROOM SUPPLEMENTS 33
6.4.2 SUPPLY CHAIN DISRUPTION DUE TO COVID-19 33
7 IMPACT OF COVID-19 ON THE EUROPE MEDICINAL MUSHROOM MARKET 35
7.1 IMPACT ON DEMAND 35
7.2 IMPACT ON SUPPLY CHAIN 35
7.3 IMPACT ON PRICE 36
7.4 STRATEGIC DECISIONS RELATED TO MEDICINAL MUSHROOMS 36
7.5 CONCLUSION 36
8 EUROPE MEDICINAL MUSHROOM MARKET, BY TYPE 37
8.1 OVERVIEW 38
8.2 CORDYCEPS 39
8.3 REISHI 39
8.4 HERICIUM 39
8.5 CHAGA 40
8.6 AURICULARIA 40
9 EUROPE MEDICINAL MUSHROOM MARKET, BY PRODUCT TYPE 41
9.1 OVERVIEW 42
9.2 ORGANIC 43
9.3 INORGANIC 43
10 8. EUROPE MEDICINAL MUSHROOMS MARKET, BY FORM 44
10.1 OVERVIEW 45
10.2 CAPSULES 46
10.3 TINCTURES 46
10.4 TABLET 46
10.5 POWDER 46
11 EUROPE MEDICINAL MUSHROOM MARKET, BY THERAPEUTIC APPLICATION 48
11.1 OVERVIEW 49
11.2 CANCER TREATMENT 50
11.3 CARDIOVASCULAR 50
11.4 IMMUNITY 50
11.5 ANTIOXIDANT, ANTIVIRAL, ANTIMICROBIAL 51
11.6 GASTROINTESTINAL 51
11.7 PHYSICAL PERFORMANCE 51
11.8 CHOLESTEROL 51
11.9 OTHERS 52
12 EUROPE MEDICINAL MUSHROOM MARKET, BY COUNTRY 53
12.1 GERMANY 57
12.2 U.K. 59
12.3 AUSTRIA 61
12.4 ITALY 63
12.5 FRANCE 65
12.6 RUSSIA 67
12.7 NETHERLANDS 69
12.8 SWITZERLAND 71
12.9 BELGIUM 73
12.10 TURKEY 75
12.11 LUXEMBOURG 77
12.12 REST OF EUROPE 79
13 EUROPE MEDICINAL MUSHROOM MARKET: COMPANY LANDSCAPE 80
13.1 COMPANY SHARE ANALYSIS: EUROPE 80
14 SWOT ANALYSIS 81
15 COMPANY PROFILE 82
15.1 NORDIC MUSHROOMS 82
15.1.1 COMPANY SNAPSHOT 82
15.1.2 PRODUCT PORTFOLIO 82
15.1.3 RECENT DEVELOPMENT 82
15.2 NYISHAR 83
15.2.1 COMPANY SANPSHOT 83
15.2.2 PRODUCT PORTFOLIO 83
15.2.3 RECENT DEVELOPMENT 84
15.3 MYCOMEDICA D.O.O. 85
15.3.1 COMPANY SNAPSHOT 85
15.3.2 PRODUCT PORTFOLIO 85
15.3.3 RECENT DEVELOPMENT 85
15.4 MYKO SAN 86
15.4.1 COMPANY SNAPSHOT 86
15.4.2 PRODUCT PORTFOLIO 86
15.4.3 RECENT DEVELOPMENT 86
15.5 MYCOTRITION GMBH 87
15.5.1 COMPANY SANPSHOT 87
15.5.2 PRODUCT PORTFOLIO 87
15.5.3 RECENT DEVELOPMENT 87
15.6 ALOHA MEDICINALS 88
15.6.1 COMPANY SNAPSHOT 88
15.6.2 PRODUCT PORTFOLIO 88
15.6.3 RECENT DEVELOPMENT 88
15.7 PILZE WOHLRAB GMBH & CO. KG 89
15.7.1 COMPANY SANPSHOT 89
15.7.2 PRODUCT PORTFOLIO 89
15.7.3 RECENT DEVELOPMENT 89
15.8 SAINT CHARLES 90
15.8.1 COMPANY SNAPSHOT 90
15.8.2 PRODUCT PORTFOLIO 90
15.8.3 RECENT DEVELOPMENT 90
15.9 SUNTORY BEVERAGE & FOOD ASIA PTE LTD 91
15.9.1 COMPANY SNAPSHOT 91
15.9.2 PRODUCT PORTFOLIO 91
15.9.3 RECENT DEVELOPMENT 91
15.10 TYROLER GLCKSPILZE 92
15.10.1 COMPANY SNAPSHOT 92
15.10.2 PRODUCT PORTFOLIO 92
15.10.3 RECENT DEVELOPMENT 93
16 QUESTIONNAIRE 94
17 RELATED REPORTS 97

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.